The combination of carfilzomib, lenalidomide, and low-dose dexamethasone has been shown to be highly active in patients with newly diagnosed multiple myeloma and provides rapid and deep responses, according to a presentation at the 2012 Annual Meeting of the American Society of Clinical Oncology. Extended treatment was well tolerated and resulted in improved depth of response, with a high stringent complete response rate and a significant proportion of patients without evidence of minimal residual disease.
Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with multiple myeloma.
After participating in this educational activity, participants should be better able to:
- Compare the efficacy and safety of regimens that contain an immunomodulatory agent and a proteasome inhibitor as initial treatment of newly diagnosed multiple myeloma (MM).
- Assess the response rates for pomalidomide in combination with low-dose dexamethasone in refractory MM patients unresponsive to transplantation.
Click Next to begin the activity.